###begin article-title 0
###xml 26 29 26 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Failure to upregulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia
###end article-title 0
###begin p 1
###xml 123 126 123 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 227 230 227 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 393 396 391 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 487 490 485 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 680 681 676 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 804 807 798 801 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 939 942 931 934 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1160 1163 1148 1151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1493 1496 1473 1476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1621 1624 1601 1604 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 551 556 <span type="species:ncbi:9606">women</span>
###xml 715 720 <span type="species:ncbi:9606">women</span>
###xml 757 765 <span type="species:ncbi:9606">patients</span>
###xml 913 918 <span type="species:ncbi:9606">women</span>
###xml 1115 1123 <span type="species:ncbi:9606">Patients</span>
###xml 1566 1571 <span type="species:ncbi:9606">women</span>
Pre-eclampsia is a pregnancy related condition characterised by hypertension, proteinuria and endothelial dysfunction. VEGF165b, formed by alternative splicing of vascular endothelial growth factor (VEGF) pre-mRNA inhibits VEGF165 mediated vasodilatation and angiogenesis, but has not been quantified in pregnancy. Enzyme-linked immunoassays (ELISA) were used to measure mean+/-SEM plasma VEGF165b, soluble endoglin (sEng) and soluble Flt1 (sFlt-1). At 12 weeks gestation the plasma VEGF165b concentration was significantly upregulated in plasma from women who maintained normal blood pressure throughout their pregnancy (normotensive group 4.90 +/-1.6 ng/ml, p<0.01 Mann-Whitney U test) compared with non-pregnant women (0.40+/-0.22ng/ml). In contrast, in patients who later developed pre-eclampsia VEGF165b levels were lower than in the normotensive group (0.467 +/-0.21 ng/ml) but no greater than non-pregnant women. At term plasma VEGF165b concentrations was greater than normal in both pre-eclamptic (3.75 +/-2.24 ng/ml) and normotensive pregnancies (10.6ng/ml+/-3.84 ng/ml p>0.1 compared with pre-eclampsia). Patients with a lower than median plasma VEGF165b at 12 weeks, had elevated soluble fms-like tyrosine kinase receptor 1 (sFlt-1) and soluble endoglin (sEng) pre-delivery. Concentrations of sFlt-1 (1.20+/-0.07 ng/ml and 1.27+/-0.18ng/ml) and sEng (4.4+/-0.18 vs 4.1+/-0.5) were similar at 12 weeks gestation in the normotensive and pre-eclamptic groups, respectively. Plasma VEGF165b levels were elevated in pregnancy, but this elevation is delayed in women that subsequently develop pre-eclampsia. Low VEGF165b may therefore be a clinically useful first trimester plasma marker for increased pre-eclampsia risk.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">1</xref>
###xml 667 668 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">2</xref>
###xml 670 671 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R3">3</xref>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 829 830 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R5">5</xref>
Pre-eclampsia, the pregnancy related disease of hypertension, proteinuria and oedema is responsible for around 12% of the world's annual 514,000 maternal deaths [1]. Aside from maternal and fetal death, the condition may also result in intra-uterine growth restriction, seizures (eclampsia), renal or liver failure, and placental abruption. Despite much investigation, the pathological processes underlying this disease are still largely undiscovered. Recent investigation had focussed on defective placental implantation as an important aetiological factor, with the resulting release of placentally derived circulating factors, which cause endothelial dysfunction [2, 3, 4]. At the microvascular level, there is a state of vasoconstriction from smooth muscle contraction, increased vascular permeability and anti-angiogenesis [5], which correspond to the clinical findings of high blood pressure, oedema and a characteristically small placenta at delivery of the baby.
###end p 3
###begin p 4
###xml 333 336 333 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 342 345 342 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 380 383 380 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 422 425 422 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 717 718 717 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 782 783 782 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R7">7</xref>
The vascular endothelial growth factor (VEGF) family is thought to be one of the important molecular systems involved in the pathogenesis of pre-eclampsia. Conventional VEGF; also known as VEGF-A, is made up of 6 different isoforms formed from alternative exon splicing resulting in proteins of varying amino acid length, termed VEGFxxx. VEGF165 is the most common isoform of VEGFxxx, and consists of 165 amino acids. VEGF165 acts via its receptor VEGFR-2 to increase vascular permeability, vasodilatation and angiogenesis [6]. Endogenous alternative splicing of the VEGF receptor results in soluble VEGFR-1 (also known as soluble fms-like tyrosine kinase 1 or sFlt-1), which binds to VEGF and inhibits its function [6]. High levels of sFlt-1 have been documented in pre-eclampsia [7].
###end p 4
###begin p 5
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R8">8</xref>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">9</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">10</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11">11</xref>
VEGF levels in pre-eclampsia have been measured by a number of techniques, with conflicting results according to the technique used. When measured by commercial sandwich Enzyme Linked ImmunoSorbent Assays (ELISAs) which has been proposed to measure only the free, unbound forms of VEGF, levels appear to be reduced in pre-eclampsia [8, 9]. When measured by radioimmunoassay (RIA) or competitive enzyme immuno assay (cEIA), VEGF levels are shown to substantially increase. This discrepancy has been proposed to be due to these latter 2 methods not being affected by circulating binding proteins [10,11].
###end p 5
###begin p 6
###xml 78 81 78 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R12">12</xref>
###xml 313 316 313 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 368 371 368 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 418 421 418 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 583 586 583 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 767 770 767 770 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 801 804 801 804 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 850 853 850 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 975 978 975 978 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 988 991 988 991 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1018 1021 1018 1021 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1120 1123 1120 1123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
In 2002, an alternative family of VEGF-A isoforms were identified, termed VEGFxxxb. These are the same size as conventional VEGF-A but are alternatively spliced in exon 8 [12], This alternative splice site selection results in an alternate 6 amino acid C terminus, which affects the property of the isoforms. VEGF165b is the most widely studied of these isoforms. VEGF165b has been shown to inhibit the effects of VEGF165 by binding to its principal receptor VEGFR-2 and preventing it from exerting its physiological effects such as endothelial cell proliferation and migration. VEGF165b also binds to and activates Flt-1 (VEGFR-1) resulting in a transient increase in capillary hydraulic conductivity, but no sustained increase in permeability, in contrast with VEGF165 [13]. A previous study of VEGF165b in term placenta detected a decrease in VEGFxxxb expression in pre-eclamptic placenta compared with control placenta, and an uncoupling of the splicing link between VEGF165b and VEGF165. To determine whether VEGF165b may play a role in the pathogenesis of pre-eclampsia, we have investigated the expression of VEGF165b in maternal plasma from normotensive and pre-eclamptic pregnancies.
###end p 6
###begin title 7
Methods
###end title 7
###begin p 8
###xml 506 509 506 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1701 1704 1689 1692 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 810 818 <span type="species:ncbi:9606">patients</span>
###xml 1264 1272 <span type="species:ncbi:9606">patients</span>
Pregnant subjects were recruited from St Michael's Maternity Hospital, Bristol between June 2006 and December 2007. 18 non-pregnant females aged between 20 and 39 years were recruited from the University of Bristol. The protocol for this study was granted ethical approval by Central and South Bristol Research Ethics Committee. 50 subjects were recruited from routine antenatal clinics in the first trimester of pregnancy. Subjects were aged between 17 and 42 years. Blood was taken from subjects for VEGF165b quantification at recruitment, and at a further 3 times at 28, 34 and 37 weeks gestation. Pre-eclampsia was defined as BP >/=140/90mmHg on </= 2 occasions measured 6 hours apart and >/=300mg of proteinuria/24 hours, in the absence of a urinary tract infection, occurring after 20 weeks gestation. 5 patients who later developed pre-eclampsia had further blood taken at disease diagnosis. Following venepuncture, blood was immediately centrifuged at 4000rpm for 10 minutes, the supernatant removed and stored at -80 degreesC until protein quantification. Subjects also received fetal growth ultrasound scans at 28, 34 and 37 weeks gestation to screen for intra-uterine growth restriction secondary to pre-eclampsia. During the study period, a further 20 patients who developed pre-eclampsia in the third trimester were recruited into the study at disease diagnosis, and received fetal growth scans at the point of recruitment into the study. In these cases plasma from their first trimesters was obtained from aliquots of frozen plasma stored under the same standard blood storage conditions by the hospital's virology department. Sample size was calculated to see an 80% change in mean VEGF165b levels at p<0.05 with a power of >90% given a standard deviation equivalent to the mean (calculated using G Power).
###end p 8
###begin title 9
###xml 4 7 4 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
VEGF165b ELISA
###end title 9
###begin p 10
###xml 9 12 9 12 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 266 269 265 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 452 455 449 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1223 1224 1215 1216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1226 1227 1218 1219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1462 1465 1453 1456 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1510 1513 1501 1504 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1552 1555 1543 1546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1747 1750 1738 1741 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1789 1792 1780 1783 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1875 1878 1866 1869 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1937 1939 1928 1930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R25">25</xref>
###xml 2009 2012 2000 2003 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xxx</sub>
###xml 2250 2253 2241 2244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 2486 2489 2477 2480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 256 261 <span type="species:ncbi:9606">human</span>
###xml 765 770 <span type="species:ncbi:9606">human</span>
###xml 2545 2553 <span type="species:ncbi:9606">patients</span>
Anti-VEGFxxxb antibody (MAB3045, clone 56/1, R&D systems) was coated onto the surface of a sterile Immulon-2HB 96 well plate at a concentration of 200mug/ml overnight. This antibody recognises an epitope within a 9 amino acid sequence at the C terminus of human VEGF165b. The plate was washed 3 times with PBS-Tween 0.05%, 100mul/well. The plate was blocked for 12 hours with Superblock (250mul/well, Pierce 37515). Serial dilutions of recombinant VEGF165b standards (R&D systems) diluted in PBS/BSA up to a concentration of 16ng/ml were then added to the wells in triplicate (200mul/well). Plasma samples were also added in triplicate (200mul/well). Plates were then incubated at room temperature with shaking for 2 hours and then washed as above. 50ng/ml of anti-human VEGF biotinylated affinity purified polyclonal antibody (BAF293, R&D systems) was added (200mul/well) and incubated at room temperature with shaking in foil for 2 hours as a detection reagent. Following a further wash, 100mul HRP-streptavidin diluted 1 in 200 in PBS was added for 20 minutes protected from light, and then substrates A and B (100mul/well) were added following washing. After 25 minutes the colour change was stopped on addition of 1M H2SO4 (50mul/well) and plates were read immediately at a wavelength of 450nm using a plate photospectrometer (Dynex Technologies). Revelation Quicklink 4.25 software was used to construct a standard curve from mean absorbance values of VEGF165b standards, which enabled estimation of VEGF165b concentration in plasma samples. VEGF165b sample concentrations were quantified at multiple different concentrations to ensure values were in the range of the ELISA, in triplicate. This sandwich ELISA measures total circulating VEGF165b. It has been shown not to detect VEGF165 and sFlt-1 is known not to interfere due to the use of antibodies against the VEGF165b molecule with epitopes at different parts of the molecule25. The coefficients of variation (CV) of this assay in quantifying VEGFxxxb was 17% for within subject variation (samples taken at least a week apart), and 7% for within sample variation, whereas between sample CV was >200%, indicating consistency of assay, and significant variation amongst the population. VEGF165b concentration in maternal plasma was quantified at 8-12 weeks, 28, 34 and 37 weeks gestation in 45 normotensive subjects and 4 subjects recruited in the first trimester who later developed pre-eclampsia in the third trimester. VEGF165b concentration was also quantified in 21 pre-eclamptic patients at 12 weeks gestation, and again in the third trimester at disease diagnosis. This ELISA is now available as a DuoSet Kit from R&D Systems.
###end p 10
###begin title 11
Endoglin and sFlt-1 ELISAs
###end title 11
###begin p 12
ELISAs for soluble endoglin and sFlt-1 were carried out on maternal plasma samples using commercial ELISA kits from R&D Systems (DNDG00 and DVR100B respectively) according to the manufacturer's instructions.
###end p 12
###begin title 13
Total VEGF ELISA and EIA
###end title 13
###begin p 14
###xml 413 421 <span type="species:ncbi:9606">patients</span>
Total circulating VEGF was quantified by commercial ELISA (Alpco Diagnostics, 45-VEGFH-0111) and by competitive enzyme immunoassay (Calbiochem, QIA69). The EIA measures both bound and free forms of VEGF. Competitive EIAs for total VEGF quantification have not been commercially available since 2006 and we had access to only a single 96 well EIA. For this reason total VEGF quantification was possible in only 10 patients. For each plasma sample, VEGF concentration was determined both by ELISA and EIA.
###end p 14
###begin title 15
Results
###end title 15
###begin p 16
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 492 500 <span type="species:ncbi:9606">patients</span>
During the study period, 100 patients were recruited. 25 patients had pre-eclampsia, and 45 remained normotensive. Of the 30 recruits who were excluded from the study, 5 developed pregnancy induced hypertension, 1 developed idiopathic fetal growth restriction, 9 patients chose not to attend follow up appointments due to social reasons, 2 patients experienced intrauterine deaths at 21 and 28 weeks gestation, 3 patients experienced preterm labour in the absence of pre-eclampsia, and in 10 patients with pre-eclampsia no first trimester blood sample was available.
###end p 16
###begin p 17
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 56 68 <span type="species:ncbi:9606">participants</span>
Table 1 shows the clinical characteristics of the study participants.
###end p 17
###begin title 18
###xml 14 17 14 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Increased VEGF165b in pregnancy
###end title 18
###begin p 19
###xml 11 14 11 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 125 128 123 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 48 53 <span type="species:ncbi:9606">women</span>
Plasma VEGF165b concentration from non-pregnant women was 0.4+/-0.22ng/ml. In the normotensive group, circulating plasma VEGF165b at 12 weeks gestation was significantly raised (4.90 +/-1.66 ng/ml, p<0.001), and remained so throughout pregnancy.
###end p 19
###begin title 20
###xml 28 31 28 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Reduced first trimester VEGF165b in patients who later develop pre-eclampsia
###end title 20
###begin p 21
###xml 37 40 37 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 240 241 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 255 257 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1a</xref>
###xml 262 264 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5a</xref>
###xml 358 361 356 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 507 510 505 508 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 694 697 686 689 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 822 823 812 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 830 839 820 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1B</xref>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
At 12 weeks gestation the plasma VEGF165b concentration was significantly lower in patients who later developed pre-eclampsia (0.467+/-0.209 ng/ml) compared with plasma from normotensive pregnancies [p<0.0047, as determined by Mann-Whitney U test, Figure 1a and 5a]. When the severe, early onset pre-eclampsia sub group was analysed, low first trimester VEGF165b concentration was also predictive at 12 weeks (Mann Whitney U, p=0.008). In contrast, at term there was no significant difference in plasma VEGF165b concentrations between pre-eclamptic (3.75+/-2.24 ng/ml) and normal pregnancies (10.58 +/-3.74 ng/ml). Thus, pre-eclampsia was associated with an 8+/-1.8 fold increase in plasma VEGF165b from first trimester to pre-delivery, compared with a 2+/-0.3 fold increase in normotensive plasma [p<0.0012, Mann-Whitney U test, Figure 1B].
###end p 21
###begin p 22
###xml 45 48 45 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 316 325 308 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2a</xref>
###xml 458 474 450 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5b and 5c</xref>
###xml 619 620 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 627 644 619 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figures 2b and 2c</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 587 595 <span type="species:ncbi:9606">patients</span>
Patients with a lower than median plasma VEGF165b at 12 weeks, had elevated sFlt-1 and sEng just before delivery. Concentrations of sFlt-1 (1.20+/-0.07 ng/ml and 1.27+/-0.18ng/ml) and sEng (4.4+/-0.18 vs. 4.1+/-0.5ng/ml) were similar at 12 weeks gestation in the normotensive and pre-eclamptic groups, respectively [Figure 2a]. Therefore, at 12 weeks gestation, neither sFlt-1 nor sEng were able to predict the onset of pre-eclampsia later in the pregnancy [Figure 5b and 5c]. At disease diagnosis however, both sEng and sFlt-1 were significantly up-regulated in comparison with healthy patients [p<0.001, Mann Whitney U test, Figures 2b and 2c].
###end p 22
###begin title 23
###xml 4 7 4 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
VEGF165b predicts sFLT-1 and sEndoglin
###end title 23
###begin p 24
###xml 42 45 42 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 177 180 177 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
The reduced first trimester levels of VEGF165b are able to predict the elevated sFLT-1, which occurs with the onset of pre-eclampsia[p=0.028, Mann-Whitney U Test]. However, VEGF165b concentration in the first trimester does not correlate with the elevated sEndoglin of pre-eclampsia.
###end p 24
###begin title 25
Commercial total VEGF ELISAs underestimate total VEGF levels
###end title 25
###begin p 26
###xml 216 232 216 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3a and 3b</xref>
Total circulating VEGF was quantified in the same plasma samples both by commercial ELISA and EIA. When quantified by ELISA, VEGF concentrations were on average 2500 fold lower than when quantified by EIA [p<0.0001, Figure 3a and 3b].
###end p 26
###begin title 27
###xml 4 7 4 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
VEGF165b accounts for the majority of total circulating VEGF in the third trimester in pre-eclamptic pregnancy
###end title 27
###begin p 28
###xml 61 64 61 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 106 109 106 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 241 244 241 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 388 396 384 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">figure 5</xref>
###xml 436 439 432 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 5 13 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 545 552 <span type="species:ncbi:9606">patient</span>
In 5 patients from each group we were able to quantitate VEGF165b and total VEGF in the same samples. VEGF165b expression increased in both pre-eclampsia and normotensive pregnancy with increasing gestational age. At 12 weeks gestation, VEGF165b accounts for 10.5+/-20% of total plasma VEGF in patients that went on to develop pre-eclampsia, compared with 18.1+/-10% in control patients (figure 5). With the onset of pre-eclampsia, VEGF165b accounted for the majority of total circulating VEGF, comprising 69.3+/-21% of total plasma VEGF in the patient group and 49+/-12% in the control group.
###end p 28
###begin title 29
###xml 4 7 4 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
VEGF165b levels at 12 weeks predict pre-eclampsia
###end title 29
###begin p 30
###xml 26 29 26 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 684 693 684 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">figure 5A</xref>
###xml 703 706 703 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
To determine which of VEGF165b, sFlt1 and endoglin are more accurate prognostic factors, receiver operating characeteristic (ROC curves) were generated by calculating sensitivity (proportion of times that the test predicts pre-eclampsia) and specificity (proportion of times that the test excluded pre-eclampsia). Thus a high sensitivity value would include all patients, but if not discriminatory, would provide a low specificity value (would include false positives). Thus non discriminatory test would give a straight line with a slope of 1 and area under the curve of 0.5 (dotted line). A perfect discriminatory test would have an area under the curve of 1.0. It can be seen from figure 5A that VEGF165b levels have an area under the curve significantly greater than 0.5, in contrast to sflt and sEng.
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R14">14</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R20">20</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R21">21</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R22">22</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11">11</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">10</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R23">23</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R24">24</xref>
###xml 1086 1088 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R25">25</xref>
###xml 1236 1239 1236 1239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1288 1291 1288 1291 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
There have been a number of studies investigating the VEGF family of proteins in pre-eclampsia [4,14,20], which have suggested that they may play a role in its pathophysiology [21,22]. The total VEGF levels measured by EIA are consistent with those previously measured using this assay methodology [11], and by those using an independent method, the radioimmunoassay [10]. In contrast the ELISA results from the same samples gave much lower readings, consistent with previous ELISA reports of plasma VEGF [23]. These experiments therefore highlight the previously reported discrepancy between measurements of total circulating VEGF in plasma by commercial ELISAs compared with cEIA, or RIA [24]. The antibodies used in the ELISA are two monoclonals raised against the VEGF peptide sequence and thus may be raised against a similar or identical epitope. The ELISA appears to yield artificially low results, presumably as VEGF is bound by agents in plasma which prevent its detection by both antibodies simultaneously. sFlt-1 does not affect this ELISA when given as recombinant protein [25], but the effect of endoglin or other plasma constituents have not been tested. The discrepancy was particularly striking after measurement of VEGF165b levels, using an ELISA that detects plasma VEGF165b using two antibodies that have epitopes on completely separate parts of the antigen (VEGF) molecule. It is therefore rather disturbing that the cEIA is no longer commercially available and was withdrawn from sale by all known suppliers between 2006 and 2007.
###end p 32
###begin p 33
###xml 24 27 24 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 58 59 58 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R15">15</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R7">7</xref>
###xml 646 647 643 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 656 657 650 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 761 763 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R16">16</xref>
###xml 949 951 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R17">17</xref>
###xml 1017 1019 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R15">15</xref>
###xml 556 560 <span type="species:ncbi:10116">rats</span>
###xml 735 739 <span type="species:ncbi:10116">rats</span>
Of the VEGF family, VEGF165 the most widely studied form [6] is known to increase vascular leakage, induce vasodilatation and promote angiogenesis. Although this isoform is up-regulated in pre-eclampsia, its metabolic activities may be blocked by other proteins, which bind to VEGF and inhibit its function. sFlt-1 and sEng both bind to VEGF and prevent it from exerting its physiological effects [15] . sFlt-1 is an antiangiogenic molecule that is able to induce a pre-eclamptic-like syndrome of hypertension and proteinuria when administered to pregnant rats [7]. sEng is an anti-angiogenic protein that inhibits transforming growth factor beta1 and beta3 signalling and increases the severity of pre-eclampsia occurring in pregnant rats treated with sFlt-1 [16]. However, neither molecule can be used clinically as a first trimester marker of pre-eclampsia as sFlt-1 levels are seen to rise only 5 weeks before the onset of the clinical disease [17], and sEng concentrations become elevated at 17 weeks gestation [15].
###end p 33
###begin p 34
###xml 12 15 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R25">25</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R26">26</xref>
###xml 211 214 211 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R12">12</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R18">18</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R25">25</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R27">27</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R26">26</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R28">28</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R29">29</xref>
###xml 587 590 587 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 653 656 653 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R30">30</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R31">31</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R18">18</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R32">32</xref>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R25">25</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R30">30</xref>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R32">32</xref>
###xml 868 871 868 871 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 940 942 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R18">18</xref>
###xml 170 175 <span type="species:ncbi:9606">human</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 705 710 <span type="species:ncbi:10090">mouse</span>
###xml 740 743 <span type="species:ncbi:10116">rat</span>
In 2002 VEGF165b was identified in normal renal cortex, and subsequently shown to be present in many different tissues, and forms the majority of VEGF in tissues such as human colon [25], and vitreous [26]. VEGF165b is relatively downregulated in many conditions, including prostate, renal, bowel, and skin cancers [12,18,25,27], diabetic retinopathy [26], Denys Drash Syndrome [28] and in the placenta of patients with pre-eclampsia [29]. The mechanisms underlying these changes in expression are still under investigation, but the reduction is associated with excess angiogenesis. VEGF165b has been shown to be anti-angiogenic in animal models of VEGF165 induced blood vessel growth in the cornea [30], mouse subcutaneous tissue [31] and rat mesentery [18] and inhibits physiological [32], and pathological [25, 30,32] angiogenesis. Studies have also shown that VEGF165b transiently, but not chronically increases hydraulic conductivity [18].
###end p 34
###begin p 35
###xml 41 44 41 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 192 195 192 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R19">19</xref>
The results shown here indicate that VEGF165b fails to be upregulated in the first trimester in those pregnancies that will later be complicated by pre-eclampsia. It can be concluded that VEGF165b may be a clinically useful first trimester marker for increased pre-eclampsia risk, providing for instance a guide to commencement of first trimester oral aspirin therapy, as this decreases the incidence of pre-eclampsia by 15% [19].
###end p 35
###begin p 36
###xml 54 57 54 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 391 394 391 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 584 587 584 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 103 108 <span type="species:ncbi:9606">women</span>
It is not clear what mediates the upregulation of VEGF165b in early pregnancy, nor what prevents it in women who will develop pre-eclampsia, and further work must be done to investigate this finding. The failure of upregulation may be reflective of the aetiology, or could be contributory to the subsequent pre-eclampsia. For instance, in the first trimester the reduced anti-angiogenic VEGF165b compared with normal pregnancy may reflect a maternal vasculature response to try and correct the defective implantation processes underlying the disease, or the failure to upregulate VEGF165b may contribute to defective implantation.
###end p 36
###begin title 37
Acknowledgements
###end title 37
###begin p 38
###xml 36 41 <span type="species:ncbi:9606">women</span>
The authors would like to thank the women who donated their time and their plasma to this study. This work was supported by the British Heart Foundation (FS/05/100, BS06/005) and the Wellcome Trust (74702).
###end p 38
###begin title 39
References
###end title 39
###begin article-title 40
WHO analysis of causes of maternal death: a systematic review
###end article-title 40
###begin article-title 41
###xml 43 48 <span type="species:ncbi:9606">human</span>
Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?
###end article-title 41
###begin article-title 42
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia
###end article-title 42
###begin article-title 43
Circulating angiogenic factors and the risk of preeclampsia
###end article-title 43
###begin article-title 44
Pre-eclampsia: clinical manifestations and molecular mechanisms
###end article-title 44
###begin article-title 45
Vascular endothelial growth factor: basic science and clinical progress
###end article-title 45
###begin article-title 46
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
###end article-title 46
###begin article-title 47
Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia
###end article-title 47
###begin article-title 48
Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery
###end article-title 48
###begin article-title 49
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop
###end article-title 49
###begin article-title 50
The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia
###end article-title 50
###begin article-title 51
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma
###end article-title 51
###begin article-title 52
###xml 37 40 37 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo
###end article-title 52
###begin article-title 53
VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia
###end article-title 53
###begin article-title 54
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
###end article-title 54
###begin article-title 55
Soluble endoglin contributes to the pathogenesis of preeclampsia
###end article-title 55
###begin article-title 56
Circulating angiogenic factors and the risk of preeclampsia
###end article-title 56
###begin article-title 57
###xml 4 7 4 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression
###end article-title 57
###begin article-title 58
Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review
###end article-title 58
###begin article-title 59
VEGF expression in the placenta from pregnancies complicated by hypertensive disorders
###end article-title 59
###begin article-title 60
###xml 107 110 <span type="species:ncbi:10116">rat</span>
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia
###end article-title 60
###begin article-title 61
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Exogenous vascular endothelial growth factor can induce preeclampsia-like symptoms in pregnant mice
###end article-title 61
###begin article-title 62
Plasma markers of angiogenesis in pregnancy induced hypertension
###end article-title 62
###begin article-title 63
Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins
###end article-title 63
###begin article-title 64
VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
###end article-title 64
###begin article-title 65
Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor
###end article-title 65
###begin article-title 66
Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma
###end article-title 66
###begin article-title 67
Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome
###end article-title 67
###begin article-title 68
The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term
###end article-title 68
###begin article-title 69
###xml 98 102 <span type="species:ncbi:10090">mice</span>
VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice
###end article-title 69
###begin article-title 70
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
###end article-title 70
###begin article-title 71
Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b
###end article-title 71
###begin article-title 72
Management of fetal growth restriction
###end article-title 72
###begin title 73
Figures and Table
###end title 73
###begin p 74
###xml 19 22 19 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 77 80 77 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 480 483 480 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 548 551 548 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 639 645 639 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(n=25)</italic>
###xml 639 645 639 645 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>(n=25)</italic></bold>
###xml 660 661 660 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 120 125 <span type="species:ncbi:9606">women</span>
###xml 198 203 <span type="species:ncbi:9606">women</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 450 458 <span type="species:ncbi:9606">patients</span>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
Measurement of VEGF165b levels in human plasma. A. At 12 weeks gestation VEGF165b was increased in plasma from pregnant women who went on to have normotensive pregnancies compared with non-pregnant women (n=45). This was not the case in patients who subsequently developed severe, early onset and non severe preeclampsia (n=25), One way Anova, Kruskal Wallis test p=0.0003. Subgroup analysis of severe/early onset pre-eclampsia (n=9) vs normotensive patients also showed that VEGF165b is significantly lowered, Mann-Whitney U test, p=0.008. B. VEGF165b levels in both pre-eclamptic and normal patients was increased in the third trimester (n=25). Mann-Whitney U Test, p=0.0012.
###end p 74
###begin p 75
###xml 577 578 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
First trimester sFlt-1 and sEng do not predict increased risk of pre-eclampsia. At 12 weeks gestation, healthy subjects and subjects who later developed pre-eclampsia had similar levels of both sFlt-1 and sEng. Neither plasma marker was able to predict pre-eclampsia at 12 weeks gestation. Pre-eclampsia is associated with up-regulation of maternal plasma levels of B. sFlt-1 and C, sEng relative to first trimester levels. In normotensive pregnancy plasma levels of both molecules increase with advancing gestational age by 2.8 fold (sEng) and 5.3 fold (sFlt-1). Mann-Whitney U Test, p<0.001.
###end p 75
###begin p 76
###xml 28 31 28 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 209 212 209 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Lack of upregulation of VEGF165b in the first trimester is able to predict the elevated sFlt-1 concentration occurring with the onset of pre-eclampsia. Mann-Whitney U test, 0.028. However, first trimester VEGF165b does not correlate with sEndoglin concentration at pre-eclampsia diagnosis.
###end p 76
###begin p 77
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(n=10)</italic>
###xml 148 154 148 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>(n=10)</italic></bold>
Total VEGF was quantified both by EIA (shown in grey) and ELISA (shown in black) in maternal plasma from normotensive and pre-eclamptic pregnancies (n=10). Detectable levels are 2500 fold lower when measured by ELISA compared to EIA, p<0.0001.
###end p 77
###begin p 78
###xml 85 88 85 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 164 167 164 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(n=10)</italic>
###xml 168 174 168 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>(n=10)</italic></bold>
###xml 238 241 238 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 303 306 303 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
The increase in VEGF levels seen during pregnancy are primarily due to increased VEGF165b. (A). At 12 weeks, only a small proportion of total VEGF (10-18%) was VEGF165b(n=10). (B). In contrast at term, approximately half the VEGF was VEGF165b in normals, and In pre-eclampsia, 70% of total VEGF was VEGF165b.
###end p 78
###begin p 79
###xml 71 74 71 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 176 179 176 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Receiver-operating characteristic (ROC) curves for first trimester VEGF165b, sFlt-1 and sEng in the prediction of pre-eclampsia. Area under the curve (AUC) was highest for VEGF165b (0.705, p=0.0047 compared with random (0.5)). AUC for sEng and sFlt-1 were 0.59 (p=0.34) and 0.56 (p=0.43) respectively, not different from random (0.5).
###end p 79
###begin p 80
###xml 38 50 <span type="species:ncbi:9606">participants</span>
Clinical characteristics of the study participants.
###end p 80
###begin p 81
Values shown are mean+/-SEM. NA, not applicable.
###end p 81
###begin p 82
###xml 1135 1137 1121 1123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 1279 1281 1265 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R33">33</xref>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
###xml 694 702 <span type="species:ncbi:9606">patients</span>
###xml 767 775 <span type="species:ncbi:9606">patients</span>
The mean maternal age within the normotensive (n=45) and pre-eclamptic (n=25) groups were 30+/-0.8 and 30+/-1.3 years respectively. There were no differences in smoking status or ethnicity between the groups. Within the pre-eclampsia group, the mean gestational age at diagnosis was 34+5+/-0.6 weeks, the mean proteinuria was 1.3 +/- 0.17g/24 hours, and the mean blood pressure was 151/98 +/-3.1/1.7mmHg. Mean birth weight within the pre-eclamptic and normotensive groups was 2513+/-166g and 3495+/-481g respectively. Of the 25 pre-eclamptic patients, 6 developed early-onset pre-eclampsia (<34 weeks gestation) and 12 developed pre-eclampsia between 34 and 37 weeks gestation. The remaining 7 patients developed pre-eclampsia at full term. 5 of the 25 pre-eclamptic patients developed severe pre-eclampsia (according to the Royal College of Obstetricians and Gynaecologists criteria: systolic BP >169mmHg or diastolic BP >109mmHg with > 1 gram proteinuria in 24 hours; or the occurrence of HELLP syndrome). 5 of the 25 fetuses born to pre-eclamptic mothers had growth restriction (ultrasonically defined as estimated fetal weight < 10th percentile for gestational age with further evidence of placental insufficiency such as oligohydramnios or abnormal umbilical artery Dopplers33).
###end p 82

